Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

By leveraging Ginkgo's ultra high throughput encapsulated screening capabilities, AgBiome aims to unlock even higher performance of its microbial strain pipeline RESEARCH TRIANGLE PARK, N.C. and BOSTON , June 6, 2023 /PRNewswire/ -- AgBiome ® , Inc., a leader in global microbial innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to optimize the performance of products in AgBiome's pipeline of agricultural biologicals.

AgBiome Leverages Ginkgo Strain Optimization Services to Optimize Agricultural Biological Pipeline

BOSTON , June 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference, on June 12, 2023, at 4:40 p.m. PT. Further details, a webcast link, and a replay of the fireside chat will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

Ginkgo Bioworks Announces Participation in Goldman Sachs 44th Annual Global Healthcare Conference

RIJSWIJK, Netherlands and BOSTON , May 25, 2023 /PRNewswire/ -- Centrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of environmentally friendly active pharmaceutical ingredients (APIs), following the success of previous work together. Ginkgo's ongoing partnership with Centrient focuses on improving the sustainability of fermentation and enzymatic syntheses of beta-lactam antibiotic APIs.

Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space

Cathie Wood is continuing to buy shares of Ginkgo Bioworks. The biofoundry's platform is scaling up, and customers are flocking.

3 Reasons Why Cathie Wood Is Buying Ginkgo Bioworks Stock Hand Over Fist

Altus Power

Standard BioTools Inc

Marqeta

FiscalNote Holdings Inc

Porch Group

If you're curious about penny stocks, they offer an interesting niche. Whether you're new to trading these stocks or expanding your investment style, understanding what to look for and how to build a strong watch list is obviously important.

7 Top Penny Stocks To Buy According To Insiders In May 2023

When it comes to investing, penny stocks have become an interesting niche. If you're new to trading these types of stocks, it's important to understand what your looking for and how to find it in order to put together a strong list of penny stocks to watch.

4 Top Penny Stocks To Buy According To Insiders In May 2023

Moderna

Viking Therapeutics

These biotech stocks are swinging for the fences. They may hit homers, they may strike out.

Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich

23andMe

Schrodinger 

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

3 Key Biotech Trends for 2023 And Beyond

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Gaurav Goparaju - Berenberg Bank Ivy Kozlowski - Goldman Sachs Anna Marie Wagner Good afternoon. I'm Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2023 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.05 per share a year ago.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

Ginkgo Bioworks (NYSE: DNA ) just reported first quarter results for 2023. Ginkgo Bioworks reported a loss per share of 11 cents.

DNA Stock Earnings: Ginkgo Bioworks Misses EPS, Beats Revenue Estimates

Ginkgo added 13 new Cell Programs to the Foundry platform in Q1 2023 Recent acquisition of the adeno-associated virus (AAV) capsid engineering platform assets of StrideBio is advancing Ginkgo's capabilities and commercial potential in gene therapy Ginkgo ended Q1 2023 with approximately $1.2 billion in cash and cash equivalents - this strong balance sheet is a strategic asset that provides Ginkgo with a multi-year runway and a margin of safety in an otherwise challenging market environment BOSTON , May 10, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2023. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports First Quarter 2023 Financial Results

COPENHAGEN, Denmark and BOSTON , May 9, 2023 /PRNewswire/ -- Octarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-stage partnership focused on compounds in the tryptophan pathway, with the objective of engineering a strain for producing violacein and its derivatives, a naturally occurring bis-indole pigment with potent bioactive properties including anti-microbial, anti-oxidant, and UV protective properties. Although initially focused on violacein, the collaboration has the potential to expand to other tryptophan-derived compounds, each with their own unique applications.

Octarine Bio and Ginkgo Bioworks Announce Partnership to Produce Natural Colors

Grab Holdings Ltd

Invitae

Trevena

Are these the best penny stocks to buy right now? Here's what's moving on Monday.

Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data

BOSTON , May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

Mr. Coen brings over 30 years of public accounting and corporate finance leadership experience, most recently as Corporate Vice President and Corporate Controller at Charles River Laboratories Marie Fallon to step down as CAO effective May 15, 2023 BOSTON , May 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Steven P. Coen, CPA, a seasoned finance executive with more than 30 years of public accounting and corporate finance leadership experience, as Chief Accounting Officer ("CAO"), effective May 15, 2023.

Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer

The bio-engineering companyexpects a sharp slowdown in revenue this year. Despite all of its partnerships, Ginkgo's business isn't overly diverse, suggesting it could have a hard time handling an economic downturn.

Down 76% From Its High, Can Ginkgo Bioworks Stock Turn Things Around?

BOSTON , May 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20, in Los Angeles. Ginkgo will present data on its high-throughput screening platform for chimeric antigen receptor (CAR) libraries, which can enable discovery of CAR variants with desired characteristics.

Ginkgo Bioworks Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Presentation and Q&A session scheduled for post-market on Wednesday, May 10, 2023 BOSTON , May 3, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of First Quarter 2023 Results Presentation

Beam Therapeutics

Block

Cerus

UiPath

Roku

Shopify

Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp deceleration in interest in various hough-growth names.

7 Best Cathie Wood Stocks for Your May 2023 Buy List

Ginkgo Bioworks still needs to prove its core business model. Ginkgo doesn't have any shortage of customers, and more are likely on the way.

Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock

Partnership aims to enable cost-effective decarbonization of rubber tire manufacturing and sustainable aviation fuel production HAYWARD, Calif. and BOSTON, April 24, 2023 /PRNewswire/ -- Visolis, a company combining advanced bioengineering with chemical catalysis to provide sustainable, carbon-negative materials, today announced a partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity.

Visolis and Ginkgo Bioworks Announce Partnership to Improve Microbial Strain for Bio-Isoprene and Sustainable Aviation Fuel Production

BOSTON , April 19, 2023 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment . The conference brings together stakeholders from across the synthetic biology community, including customers, suppliers, academics, journalists, and many more.

Ginkgo Bioworks Previews Today's Annual Ferment Conference

Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of their collaboration. Through the partnership, Cambrium and Ginkgo combined their capabilities to enable the rapid and cost-effective design of high performing, industrially relevant microbes for protein production.

Cambrium and Ginkgo Bioworks Complete Successful Collaboration on Data-Driven Cell Factory Engineering

Peabody Energy

Hanesbrands

Pool

Latham Group

In late 2020, Peabody Energy (NYSE: BTU ) was in trouble. The stock had dropped below $1 and the 138-year-old coal firm was at risk of getting delisted from its exchange.

News for Ginkgo Bioworks Holdings Stock (DNA)